Identifying the dominant prostate cancer focal lesion using image analysis and planning of a simultaneous integrated stereotactic boost

References

• Valerio M, Emberton M, Ahmed HU. Focal therapy will become a standard option for selected men with localized prostate cancer. J Clin Oncol 2014;32:3680–1.
   PubMed Web of Science ®Google Scholar
• Ahmed HU, Pendse D, Illing R, Allen C, van der Meulen JHP, Emberton M. Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol 2007;4:632–42.
   PubMedGoogle Scholar
• Djavan B, Zlotta A, Kratzik C, Remzi M, Seitz C, Schulman CC, et al. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology 1999;54:517–22.
   PubMed Web of Science ®Google Scholar
• Scales Jr. CD, Presti Jr. JC, Kane CJ, Terris MK, Aronson WJ, Amling CL, et al. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy—results from the SEARCH database. J Urol 2007;178:1249–52.
   PubMed Web of Science ®Google Scholar
• Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 2007;110:906–10.
   PubMed Web of Science ®Google Scholar
• Rothwax JT, George AK, Wood BJ, Pinto PA. Multiparametric MRI in biopsy guidance for prostate cancer: Fusion-guided. BioMed Res Int 2014;2014:e439171.
   PubMed Web of Science ®Google Scholar
• Ahmad SS, Duke S, Jena R, Williams MV, Burnet NG. Advances in radiotherapy. Br Med J 2012;345:e7765.
   PubMed Web of Science ®Google Scholar
• Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: Preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012;13:43–54.
   PubMed Web of Science ®Google Scholar
• Pluim JPW, Fitzpatrick JM. Image registration. IEEE Trans Med Imaging 2003;22:1341–3.
   PubMed Web of Science ®Google Scholar
• Thor M, Petersen JB, Bentzen L, Høyer M, Muren LP. Deformable image registration for contour propagation from CT to cone-beam CT scans in radiotherapy of prostate cancer. Acta Oncol 2011;50:918–25.
   PubMed Web of Science ®Google Scholar
• Tho rnqvist S, Petersen JB, Høyer M, Bentzen L, Muren LP. Propagation of target and organ at risk contours in radio-therapy of prostate cancer using deformable image registration. Acta Oncol 2010;49:1023–32.
   PubMed Web of Science ®Google Scholar
• Leibfarth S, Mönnich D, Welz S, Siegel C, Schwenzer N, Schmidt H, et al. A strategy for multimodal deformable image registration to integrate PET/MR into radiotherapy treatment planning. Acta Oncol 2013;52:1353–9.
   PubMed Web of Science ®Google Scholar
• Thor M, Bentzen L, Elstrøm UV, Petersen JB, Muren LP. Dose/volume-based evaluation of the accuracy of deformable image registration for the rectum and bladder. Acta Oncol 2013;52:1411–6.
   PubMed Web of Science ®Google Scholar
• Thor M, Andersen ES, Petersen JB, Sørensen TS, Noe KØ, Tanderup K, et al. Evaluation of an application for intensity-based deformable image registration and dose accumulation in radiotherapy. Acta Oncol 2014;53:1329–36.
   PubMed Web of Science ®Google Scholar
• Lowe DG. Distinctive image features from scale-invariant keypoints. Int J Comput Vis 2004;60:91–110.
   Web of Science ®Google Scholar
• Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P. Multimodality image registration by maximization of mutual information. IEEE Trans Med Imaging 1997;16:187–98.
   PubMed Web of Science ®Google Scholar
• Rueckert D, Sonoda LI, Hayes C, Hill DLG, Leach MO, Hawkes DJ. Nonrigid registration using free-form deformations: Application to breast MR images. IEEE Trans Med Imaging 1999;18:712–21.
   PubMed Web of Science ®Google Scholar
• PACE study research summary. ClincalTrials.gov Identifier: NCT01584258[Internet]. [cited 2015 Apr 29]. Available from: http://public.ukcrn.org.uk/search/StudyDetail.aspx? StudyID = 12628.
   Google Scholar
• Tree A, Jones C, Sohaib A, Khoo V, van As N. Prostate stereotactic body radiotherapy with simultaneous integrated boost: Which is the best planning method? Radiat Oncol 2013;8:228.
   PubMed Web of Science ®Google Scholar
• Li XA, Alber M, Deasy JO, Jackson A, Jee K-WK, Marks LB, et al. The use and QA of biologically related models for treatment planning: Short report of the TG-166 of the therapy physics committee of the AAPM. Med Phys 2012;39: 1386–409.
   PubMed Web of Science ®Google Scholar
• Rancati T, Fiorino C, Gagliardi G, Cattaneo GM, Sanguineti G, Borca VC, et al. Fitting late rectal bleeding data using different NTCP models: Results from an Italian multi-centric study (AIROPROS0101). Radiother Oncol 2004;73:21–32.
   PubMed Web of Science ®Google Scholar
• Cronqvist A-KA. Quantification of the response of heterogeneous tumours and organized normal tissues to fractionated radiotherapy. Ph.D. thesis, Stockholm University; 1995.
   Google Scholar
• Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, et al. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Rad Oncol Biol Phys 2005;61: 993–1002.
   PubMed Web of Science ®Google Scholar
• Sartor AO, Hricak H, Wheeler TM, Coleman J, Penson DF, Carroll PR, et al. Evaluating localized prostate cancer and identifying candidates for focal therapy. Urology 2008; 72(6 Suppl):S12–24.
   PubMed Web of Science ®Google Scholar
• Ohori M, Eastham J, Koh H, et al. Is focal therapy reasonable in patients with early stage prostate cancer (CaP)-an analysis of radical prostatectomy (RP) specimens. J Urol 2006;175 (Suppl)507(Abstract 1574).
   PubMed Web of Science ®Google Scholar
• White EC, Kamrava MR, Demarco J, Park S-J, Wang P-C, Kayode O, et al. High-dose-rate prostate brachytherapy consistently results in high quality dosimetry. Int J Radiat Oncol 2013;85:543–8.
   PubMed Web of Science ®Google Scholar
• Lagerwaard FJ, Verstegen NE, Haasbeek CJA, Slotman B, Paul MA, Smit EF, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Rad Oncol Biol Phys 2012;83:348–53.
   PubMed Web of Science ®Google Scholar
• Lanni TB, Grills IS, Kestin LL, Robertson JM. Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer. Am J Clin Oncol 2011;34:494–8.
   PubMed Web of Science ®Google Scholar
• Oliveira SM, Teixeira NJ, Fernandes L. What do we know about the alpha/beta ratio for prostate cancer? Med Phys 2012;39:3189–201.
   PubMed Web of Science ®Google Scholar
• Prostate accurately targeted radiotherapy investigation of overall treatment time – ClinicalTrials.gov Identifier: NCT01423474 [Internet]. [cited 2015 May 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT01423474.
   Google Scholar